Search
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorde...
Synonyms: (3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-?-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-?-oxo-1-piperidinepropanenitrile, (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileCategories: P-glycoprotein inhibitors, P-glycoprotein substratesSebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat . Sebetralstat is the first and only oral ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAficamten
go.drugbank.com/drugs/DB18490ApprovedInvestigationalAficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesZongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigationalZongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSunvozertinib
go.drugbank.com/drugs/DB18925InvestigationalSunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCL...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for t...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesOveporexton
go.drugbank.com/drugs/DB21680ApprovedOveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore thi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTolevamer
go.drugbank.com/drugs/DB01344ApprovedSodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical ...
Products: <p>KALQUEST® Powder for Oral Suspension 5g/sachet</p>Nicotinamide Mononucleotide
go.drugbank.com/drugs/DB03227Investigational3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. … A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]